CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: August 23, 2011
Result type: Reports
Project Number: SR0249-000
Product Line: Reimbursement Review

Generic Name: Telaprevir

Brand Name: Incivek

Manufacturer: Vertex Pharmaceuticals Inc.

Therapeutic Area: Hepatitis C, chronic

Indications: Hepatitis C infection (genotype 1), Chronic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 15, 2012

Recommendation Type: List with clinical criteria and/or conditions